Document is current
Any future updates will be listed below
-
Authors
Schroeder, Christopher https://orcid.org/0000-0002-9283-3012
Gatidis, Sergios https://orcid.org/0000-0002-6928-4967
Kelemen, Olga
Schütz, Leon https://orcid.org/0000-0001-7907-4878
Bonzheim, Irina https://orcid.org/0000-0002-7732-0788
Muyas, Francesc
Martus, Peter
Admard, Jakob https://orcid.org/0000-0003-0466-582X
Armeanu-Ebinger, Sorin
Gückel, Brigitte
Küstner, Thomas https://orcid.org/0000-0002-0353-4898
Garbe, Claus
Flatz, Lukas
Pfannenberg, Christina
Ossowski, Stephan https://orcid.org/0000-0002-7416-9568
Forschner, Andrea https://orcid.org/0000-0002-6185-4945
-
Funding
Funding for this research was provided by:
This study was supported by a research grant from the Bristol Myers Squibb Stiftung Immunonkologie (project FA 19-008).
- License Information
-
More Information
Article History
Received: 23 November 2023
Accepted: 20 September 2024
First Online: 9 October 2024
Competing interests
: A.F. reports honoraria for presentations for BMS, MSD, Novartis, Pierre-Fabre, Delcath and Immunocore; travel support and congress participation support from BMS, Pierre-Fabre, Novartis, MSD; Advisory Boards from MSD, BMS, Novartis, Pierre-Fabre, Immunocore and research funding from BMS Stiftung Immunonkologie. C.S. and S.O. report research funding from BMS Stiftung Immunonkologie as well as institutional grants and payment for conference presentations from Illumina Inc. and Oxford Nanopore Technologies outside the submitted work. The remaining authors have no conflict of interests to disclose.
